1st Quarter - Report

ALPINE GROUP PARTNERS, LLC. for ULTRAGENYX PHARMACEUTICAL INC.

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases likeDuchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD)

LobbyistCovered position, as disclosed
KEENAN AUSTIN REED —
ERIN MENDELSOHN —
SHAYNE WOODS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Government Issues GOV

Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases likeDuchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD)

LobbyistCovered position, as disclosed
KEENAN AUSTIN REED —
ERIN MENDELSOHN —
SHAYNE WOODS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medical/Disease Research/Clinical Labs MED

Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases likeDuchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD)

LobbyistCovered position, as disclosed
KEENAN AUSTIN REED —
ERIN MENDELSOHN —
SHAYNE WOODS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.